Major shareholder transaction: Notification pursuant to Section 28a of the Danish Securities Trading Act

Release no. 27/2012


Copenhagen and Oslo, 2012-09-06 16:32 CEST (GLOBE NEWSWIRE) --

In accordance with Section 28a of the Danish Securities Trading Act, this is to notify, on behalf of Alexander Shuster, Chairman of the Board of Directors of Affitech A/S, of the following transactions:

 

 

Name Trans Nova Investments Limited
Reason for reporting Related party to Alexander Shuster, Chairman of the Board of Affitech A/S
Issuer and ISIN Affitech A/S/DK0015966592
Type of transaction Purchase of shares
Relevant market NASDAQ OMX COPENHAGEN A/S
Date of transaction         5th September, 2012
Number of traded securities and market value 97,573 shares. Market value DKK 19,466
Date of transaction         6th September, 2012
Number of traded securities and market value 62,517 shares. Market value DKK 12,503

 

 

About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.

 

         Contact
         
         Randi Krogsgaard, Director IR & Communications
         
         Tel # +45 2320 1001, e-mail: ir@affitech.com


Attachments

120906_major shareholder transaction_release 27_uk.pdf